HomePublications

Suppression of Tumor Energy Supply by Liposomal Nanoparticle-Mediated Inhibition of Aerobic Glycolysis

Research output: Contribution to journalArticle

Standard

Suppression of Tumor Energy Supply by Liposomal Nanoparticle-Mediated Inhibition of Aerobic Glycolysis. / Zhang, Yinlong; Wei, Jingyan; Xu, Jiaqi; Leong, Wei Sun; Liu, Guangna; Ji, Tianjiao; Cheng, Zhiqiang; Wang, Jing; Lang, Jiayan; Zhao, Ying; You, Linhao; Zhao, Xiao; Wei, Taotao; Anderson, Greg J.; Qi, Sheng; Kong, Jing; Nie, Guangjun; Li, Suping.

In: ACS Applied Materials & Interfaces, Vol. 10, No. 3, 24.01.2018, p. 2347–2353.

Research output: Contribution to journalArticle

Harvard

Zhang, Y, Wei, J, Xu, J, Leong, WS, Liu, G, Ji, T, Cheng, Z, Wang, J, Lang, J, Zhao, Y, You, L, Zhao, X, Wei, T, Anderson, GJ, Qi, S, Kong, J, Nie, G & Li, S 2018, 'Suppression of Tumor Energy Supply by Liposomal Nanoparticle-Mediated Inhibition of Aerobic Glycolysis' ACS Applied Materials & Interfaces, vol. 10, no. 3, pp. 2347–2353. https://doi.org/10.1021/acsami.7b16685

APA

Vancouver

Author

Zhang, Yinlong ; Wei, Jingyan ; Xu, Jiaqi ; Leong, Wei Sun ; Liu, Guangna ; Ji, Tianjiao ; Cheng, Zhiqiang ; Wang, Jing ; Lang, Jiayan ; Zhao, Ying ; You, Linhao ; Zhao, Xiao ; Wei, Taotao ; Anderson, Greg J. ; Qi, Sheng ; Kong, Jing ; Nie, Guangjun ; Li, Suping. / Suppression of Tumor Energy Supply by Liposomal Nanoparticle-Mediated Inhibition of Aerobic Glycolysis. In: ACS Applied Materials & Interfaces. 2018 ; Vol. 10, No. 3. pp. 2347–2353.

Bibtex- Download

@article{df3c35a36c004f82934b0f698fbc4314,
title = "Suppression of Tumor Energy Supply by Liposomal Nanoparticle-Mediated Inhibition of Aerobic Glycolysis",
abstract = "Aerobic glycolysis enables cancer cells to rapidly take up nutrients (e.g., nucleotides, amino acids, and lipids) and incorporate them into the biomass needed to produce a new cell. In contrast to existing chemotherapy/radiotherapy strategies, inhibiting aerobic glycolysis to limit the adenosine 5′-triphosphate (ATP) yield is a highly efficient approach for suppressing tumor cell proliferation. However, most, if not all, current inhibitors of aerobic glycolysis cause significant adverse effects because of their nonspecific delivery and distribution to nondiseased organs, low bioavailability, and a narrow therapeutic window. New strategies to enhance the biosafety and efficacy of these inhibitors are needed for moving them into clinical applications. To address this need, we developed a liposomal nanocarrier functionalized with a well-validated tumor-targeting peptide to specifically deliver the aerobic glycolysis inhibitor 3-bromopyruvate (3-BP) into the tumor tissue. The nanoparticles effectively targeted tumors after systemic administration into tumor-bearing mice and suppressed tumor growth by locally releasing 3-BP to inhibit the ATP production of the tumor cells. No overt side effects were observed in the major organs. This report demonstrates the potential utility of the nanoparticle-enabled delivery of an aerobic glycolysis inhibitor as an anticancer therapeutic agent.",
keywords = "3-bromopyruvate, ATP, liposomal nanoparticles, tumor-targeting peptide, Warburg effect",
author = "Yinlong Zhang and Jingyan Wei and Jiaqi Xu and Leong, {Wei Sun} and Guangna Liu and Tianjiao Ji and Zhiqiang Cheng and Jing Wang and Jiayan Lang and Ying Zhao and Linhao You and Xiao Zhao and Taotao Wei and Anderson, {Greg J.} and Sheng Qi and Jing Kong and Guangjun Nie and Suping Li",
year = "2018",
month = "1",
day = "24",
doi = "10.1021/acsami.7b16685",
language = "English",
volume = "10",
pages = "2347–2353",
journal = "ACS Applied Materials & Interfaces",
issn = "1944-8244",
publisher = "American Chemical Society",
number = "3",

}

RIS (suitable for import to EndNote) - Download

TY - JOUR

T1 - Suppression of Tumor Energy Supply by Liposomal Nanoparticle-Mediated Inhibition of Aerobic Glycolysis

AU - Zhang, Yinlong

AU - Wei, Jingyan

AU - Xu, Jiaqi

AU - Leong, Wei Sun

AU - Liu, Guangna

AU - Ji, Tianjiao

AU - Cheng, Zhiqiang

AU - Wang, Jing

AU - Lang, Jiayan

AU - Zhao, Ying

AU - You, Linhao

AU - Zhao, Xiao

AU - Wei, Taotao

AU - Anderson, Greg J.

AU - Qi, Sheng

AU - Kong, Jing

AU - Nie, Guangjun

AU - Li, Suping

PY - 2018/1/24

Y1 - 2018/1/24

N2 - Aerobic glycolysis enables cancer cells to rapidly take up nutrients (e.g., nucleotides, amino acids, and lipids) and incorporate them into the biomass needed to produce a new cell. In contrast to existing chemotherapy/radiotherapy strategies, inhibiting aerobic glycolysis to limit the adenosine 5′-triphosphate (ATP) yield is a highly efficient approach for suppressing tumor cell proliferation. However, most, if not all, current inhibitors of aerobic glycolysis cause significant adverse effects because of their nonspecific delivery and distribution to nondiseased organs, low bioavailability, and a narrow therapeutic window. New strategies to enhance the biosafety and efficacy of these inhibitors are needed for moving them into clinical applications. To address this need, we developed a liposomal nanocarrier functionalized with a well-validated tumor-targeting peptide to specifically deliver the aerobic glycolysis inhibitor 3-bromopyruvate (3-BP) into the tumor tissue. The nanoparticles effectively targeted tumors after systemic administration into tumor-bearing mice and suppressed tumor growth by locally releasing 3-BP to inhibit the ATP production of the tumor cells. No overt side effects were observed in the major organs. This report demonstrates the potential utility of the nanoparticle-enabled delivery of an aerobic glycolysis inhibitor as an anticancer therapeutic agent.

AB - Aerobic glycolysis enables cancer cells to rapidly take up nutrients (e.g., nucleotides, amino acids, and lipids) and incorporate them into the biomass needed to produce a new cell. In contrast to existing chemotherapy/radiotherapy strategies, inhibiting aerobic glycolysis to limit the adenosine 5′-triphosphate (ATP) yield is a highly efficient approach for suppressing tumor cell proliferation. However, most, if not all, current inhibitors of aerobic glycolysis cause significant adverse effects because of their nonspecific delivery and distribution to nondiseased organs, low bioavailability, and a narrow therapeutic window. New strategies to enhance the biosafety and efficacy of these inhibitors are needed for moving them into clinical applications. To address this need, we developed a liposomal nanocarrier functionalized with a well-validated tumor-targeting peptide to specifically deliver the aerobic glycolysis inhibitor 3-bromopyruvate (3-BP) into the tumor tissue. The nanoparticles effectively targeted tumors after systemic administration into tumor-bearing mice and suppressed tumor growth by locally releasing 3-BP to inhibit the ATP production of the tumor cells. No overt side effects were observed in the major organs. This report demonstrates the potential utility of the nanoparticle-enabled delivery of an aerobic glycolysis inhibitor as an anticancer therapeutic agent.

KW - 3-bromopyruvate

KW - ATP

KW - liposomal nanoparticles

KW - tumor-targeting peptide

KW - Warburg effect

U2 - 10.1021/acsami.7b16685

DO - 10.1021/acsami.7b16685

M3 - Article

VL - 10

SP - 2347

EP - 2353

JO - ACS Applied Materials & Interfaces

JF - ACS Applied Materials & Interfaces

SN - 1944-8244

IS - 3

ER -

ID: 135834951